back to US directory
us clinical guidance

Combined hormonal contraception

CDC eligibility screening, person-centered initiation, backup and safety follow-up for pills, patches and vaginal rings.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Patients considering or using estrogen鈥損rogestin pills, patches or vaginal rings for contraception or a noncontraceptive benefit. This page supports method selection and routine follow-up; it does not replace diagnosis of acute thrombosis, stroke, pregnancy or severe abnormal bleeding.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

The Bottom Line

  • Use U.S. MEC categories to assess whether a patient鈥檚 medical condition or interacting medicine makes a combined hormonal method acceptable, relatively unfavorable or an unacceptable health risk.
  • Measure blood pressure before initiation because severe or poorly controlled hypertension can make estrogen-containing contraception unsafe; a pelvic examination and routine laboratory panel are not prerequisites for most patients.
  • Combined hormonal contraception can usually start whenever the clinician is reasonably certain the patient is not pregnant, with backup contraception determined by cycle timing and the selected method.
  • Smoking at age 35 or older, migraine with aura, current or high-risk thromboembolic disease and several cardiovascular conditions materially change eligibility and require an alternative-method discussion.
  • Present contraceptive effectiveness, bleeding effects, adherence demands and noncontraceptive benefits without coercion, and respect a patient鈥檚 decision to start, switch or stop.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Practical clinical workflow

1
Clarify pregnancy intentions, preferred bleeding pattern, ability to use a daily, weekly or monthly method, prior side effects and priorities regarding privacy, cost and noncontraceptive benefits.
2
Record blood pressure and screen for tobacco use, migraine aura, thrombosis, cardiovascular disease, breast cancer, postpartum or breastfeeding status, liver disease and interacting medications.
3
Use the U.S. MEC condition-specific category rather than a generic contraindication list, and compare progestin-only, intrauterine, implant and nonhormonal choices when estrogen risk is elevated.
4
Start the chosen formulation when pregnancy can be reasonably excluded, provide the U.S. SPR backup interval and explain formulation-specific late or missed-dose instructions.
5
Review blood pressure, adherence, bleeding and adverse effects at clinically appropriate follow-up, while enabling refills and method switching without unnecessary examinations.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Safety boundaries and escalation

  • New chest pain, shortness of breath, unilateral leg swelling, focal neurologic deficit, sudden severe headache or visual loss requires emergency assessment for thrombosis, stroke or another acute event.
  • New migraine aura, major surgery with prolonged immobilization, severe hypertension or a new interacting medicine requires prompt eligibility reassessment rather than automatic continuation.
  • Persistent pregnancy symptoms, severe pelvic pain or a positive pregnancy test requires diagnostic review; contraceptive use does not exclude ectopic or intrauterine pregnancy.
  • Combined hormonal methods do not protect against sexually transmitted infection; offer condoms, vaccination and site-appropriate screening based on exposure and risk.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Localization

This page applies CDC U.S. MEC and U.S. SPR categories, formulations and practice recommendations. FDA labeling, insurer formularies, pharmacist-prescribing authority and minor-consent rules differ across US jurisdictions.
sources for this section:CDC U.S. MEC 2024CDC U.S. SPR 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionU.S. Medical Eligibility Criteria for Contraceptive Use, 2024MMWR 2024;73(No. RR-4); DOI 10.15585/mmwr.rr7304a1 路 published 2024-08-08 路 accessed 2026-08-20
    view source
  2. Centers for Disease Control and PreventionU.S. Selected Practice Recommendations for Contraceptive Use, 2024MMWR 2024;73(No. RR-3); DOI 10.15585/mmwr.rr7303a1 路 published 2024-08-08 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.